PT  - JOURNAL ARTICLE
AU  - Mahmoud Abdelaziz
AU  - Saib Khogali
AU  - James M Cotton
AU  - Antonella Meralgia
AU  - Maciej Matuszewski
AU  - Heyman Luckraz
TI  - Transcatheter aortic valve implantation in decompensated aortic stenosis within the same hospital admission: early clinical experience
AID  - 10.1136/openhrt-2018-000827
DP  - 2018 Jul 01
TA  - Open Heart
PG  - e000827
VI  - 5
IP  - 2
4099  - http://openheart.bmj.com/content/5/2/e000827.short
4100  - http://openheart.bmj.com/content/5/2/e000827.full
SO  - Open Heart2018 Jul 01; 5
AB  - Objective Severe decompensated aortic valve stenosis is associated with noticeable reduction in survival. Until recently the options for such patients were either high-risk surgery or percutaneous balloon valvuloplasty and medical therapy which does not add any survival benefits and associated with high rate of complications. We present our experience in the use of transcatheter aortic valve implantation (TAVI) in patients with decompensated severe aortic stenosis requiring urgent intervention in the same hospital admission.Methods In this observational study, all patients who were admitted with decompensated severe aortic stenosis were enrolled. Elective patients were excluded from the study. Perioperative records were analysed and clinical, echocardiographic and survival data were presented.Results 76 patients with a mean age of 81±6 years were enrolled. All patients presented with New York Heart Association (NYHA) IV status. Femoral approach was performed in 86.8%. Median postoperative hospital stay was 6 days and intensive care unit admission rate was 15%. At follow-up, 61.8% of patients were in NYHA status I/II. Moderate or more paravalvular leak occurred in 5.2% of patients. Permanent pacemaker was required in 14.4% of patients. The incidence of in-hospital death was 2.6%. Kaplan-Meier analysis indicated a survival rate of 81% at 1 year.Conclusions Urgent in-hospital TAVI is feasible as the first-line treatment in decompensated severe aortic stenosis. In our cohort, it showed to be safe and achieved satisfactory survival rates and symptom control.